NCT03448445View on ClinicalTrials.gov

A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting

CompletedOBSERVATIONAL
Enrollment

201

Participants

Timeline

Start Date

June 22, 2018

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions
Mild Cognitive Impairment
Interventions
OTHER

Usual care setting

usual care settings without any intervention

Trial Locations (16)

Unknown

Eisai Trial site_12, Anyang

Eisai Trial site_11, Busan

Eisai Trial site_15, Busan

Eisai Trial site_08, Changwon

Eisai Trial site_09, Daegu

Eisai Trial site_05, Daejeon

Eisai Trial site_03, Gachon

Eisai Trial site_07, Guri-si

Eisai Trial site_10, Gwangju

Eisai Trial site_16, Jeju City

Eisai Trial site_01, Seoul

Eisai Trial site_02, Seoul

Eisai Trial site_04, Seoul

Eisai Trial site_06, Seoul

Eisai Trial site_13, Seoul

Eisai Trial site_14, Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT03448445 - A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting | Biotech Hunter | Biotech Hunter